VRTX: This table presents the ITT efficacy data from the Telaprevir ADVANCE trial in a different (and IMO more helpful) way than in VRTX’s PR. I’m making the simplifying assumptions that viral breakthroughs during treatment and late dropouts (i.e. after a patient achieved undetectable VL) were rare enough to ignore in this “first-order” analysis.)
‘12+12’ ‘08+16’ SoC Arm Arm 48wk (n=362)(n=364)(n=369)
RVR 68% 66% 9%
Undtctble VL achieved too late for RVR 16% 17% 63% === === === Undtctble VL at any time 84% 83% 72%
Relapse ( 9%) (10%) (28%) ===== ===== =====
SVR 75% 73% 44%
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”